id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-287680-vdrix1cp	D’Acquarica, Ilaria	Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19	2020-05-01		.txt	text/plain	1176	75	54	The strategy of chiral switches has emergedthe development of a single enantiomer from a chiral drug that has previously been developed (and often approved and marketed) as a racemate or as a mixture of diastereomers. The chiral switch of HCQ was initiated in the early 1990swith method-of-use patents US 5,314,894 (priority date 15-09-1992, assignee Sterling Winthrop, New York) and EP 0588439B1 claiming the enantiomer (S)-(+)-hydroxychloroquine [(S)-(+)-HCQ] for treatments of malaria, RA and LE. We aim preferentially at (S)-(+)-hydroxychloroquine [(S)-(+)-HCQ], the more-promising enantiomer (patents: US 5,314,894 and EP 0588430B1, proprietor Sanofi, priority date 15-09-1992, now expired), followed by (S)-(+)-chloroquine [(S)-(+)-CQ]. Our call for repurposing HCQ and/or CQ by urgently developing the chiral switches of these racemates to their (S)-(+)-enantiomers for the treatment of COVID-19 is based on the expectations of safer pharmacological profiles of the selected enantiomers, favorable risk:benefit profiles and shortened development and approval processes.	./cache/cord-287680-vdrix1cp.txt	./txt/cord-287680-vdrix1cp.txt